EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Beyond the typical immune effector cell-associated neurotoxicity syndrome: Characterizing non-immune effector cell-associated neurotoxicity syndrome neurological complications in chimeric antigen receptor T-cell therapy—A retrospective analysis

Melissa A Nicholas, Abdulaziz Abu-Haimed, Faisal Abushullaih, Emily N Davidson, Graeme A Fenton, Justin W Kehm, Hakan Kocoglu, Jean A Yared iD, Ariel Fromowitz, Nancy M Hardy iD, Aaron P Rapoport, Djordje Atanackovic und 3 weitere

Neuro-Oncology Advances · 12.01.2026 · 8 (1)

DOI: 10.1093/noajnl/vdag204 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology Advances, online erschienen am 05.08.2026. Verfasst von Melissa A Nicholas und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of relapsed/refractory hematologic malignancies. While immune effector cell-associated neurotoxicity syndrome (ICANS) is a well-recognized complication, expanding clinical use has revealed distinct non-ICANS neurological complications that challenge standard diagnostic and management approaches. We characterize the clinical features and outcomes of these non-classic presentations.

Methods

A retrospective analysis was conducted on 357 patients receiving commercial CAR-T therapy for non-Hodgkin lymphoma or multiple myeloma at a single academic center (2015-2025). Non-ICANS neurological complications were defined by neurologic deficits, movement disorders, or neurocognitive syndromes occurring in the absence of global encephalopathy (ICE scores 9-10). Institutional protocol included baseline neurology evaluation and brain MRI.

Results

Non-ICANS complications occurred in 17 patients (4.76%). Manifestations included focal neuropathies or myelopathy (n = 5), progressive leukoencephalopathy (n = 4), neuropsychiatric symptoms (n = 3), Parkinsonism (n = 2), and cranial nerve palsies (n = 4). Compared to the institutional median for classic ICANS (7 days), non-ICANS demonstrated a prolonged median duration of 14 days (range, 4-365+ days). Abnormal brain MRI findings were present in 5 of 15 (33.3%) cases with post-treatment brain MRI, manifesting commonly as T2/FLAIR hyperintensities in the white matter. Cerebrospinal fluid (CSF) immunomonitoring in a subset of cases (n = 2) revealed an enrichment of CAR T-cells compared to peripheral blood.

Conclusions

Non-ICANS neurological complications represent a distinct clinical subset characterized by atypical findings, neuroimaging abnormalities, and/or protracted recovery. Increased clinical vigilance and tailored diagnostic approaches are essential to mitigate long-term morbidity, as standard screening tools fail to capture these focal neurotoxicities.

Schlagwörter

Stichwörter der Autor:innen

CAR-T therapyICANScytokine release syndromeimmunotherapyneurotoxicity

Autor:innen und Institutionen

  • Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Department of Medicine, University of Maryland, Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA (H.K., J.A.Y., A.F., N.M.H., A.P.R., D.A., L.P., A.B., H.A.).
  • Transplant and Cellular Therapy Program, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA.
  • Department of Neurology, University of Maryland School of Medicine, Baltimore, Maryland, USA.

ORCID-Profile: Jean A Yared, Nancy M Hardy, Haroon Ahmad

Zitieren

APA

Nicholas, M. A., Abu-Haimed, A., Abushullaih, F., Davidson, E. N., Fenton, G. A., Kehm, J. W., Kocoglu, H., Yared, J. A., Fromowitz, A., Hardy, N. M., Rapoport, A. P., Atanackovic, D., Pham, L., Badros, A., & Ahmad, H. (2026). Beyond the typical immune effector cell-associated neurotoxicity syndrome: Characterizing non-immune effector cell-associated neurotoxicity syndrome neurological complications in chimeric antigen receptor T-cell therapy—A retrospective analysis. Neuro-Oncology Advances, 8(1). https://doi.org/10.1093/noajnl/vdag204

Vancouver

Nicholas MA, Abu-Haimed A, Abushullaih F, Davidson EN, Fenton GA, Kehm JW, et al. Beyond the typical immune effector cell-associated neurotoxicity syndrome: Characterizing non-immune effector cell-associated neurotoxicity syndrome neurological complications in chimeric antigen receptor T-cell therapy—A retrospective analysis. Neuro-Oncology Advances. 2026;8(1). doi:10.1093/noajnl/vdag204

BibTeX
@article{Nicholas2026,
  author = {Nicholas, Melissa A and Abu-Haimed, Abdulaziz and Abushullaih, Faisal and Davidson, Emily N and Fenton, Graeme A and Kehm, Justin W and Kocoglu, Hakan and Yared, Jean A and Fromowitz, Ariel and Hardy, Nancy M and Rapoport, Aaron P and Atanackovic, Djordje and Pham, Lily and Badros, Ashraf and Ahmad, Haroon},
  title = {Beyond the typical immune effector cell-associated neurotoxicity syndrome: Characterizing non-immune effector cell-associated neurotoxicity syndrome neurological complications in chimeric antigen receptor T-cell therapy—A retrospective analysis},
  journal = {Neuro-Oncology Advances},
  year = {2026},
  volume = {8},
  number = {1},
  doi = {10.1093/noajnl/vdag204}
}
Kostenlos starten →